A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients.

Canadian Respiratory Journal : Journal of the Canadian Thoracic Society
Wilfried H NikolaizikFelix Ratjen

Abstract

Inhaled tobramycin has been shown to improve lung function in cystic fibrosis (CF) patients chronically infected with Pseudomonas aeruginosa. However, to date no comparative data are available for different dose regimens used in clinical practice. To compare the clinical efficacy of the two most commonly used treatment regimens of inhaled tobramycin in patients with CF. In an open crossover study of CF patients, subjects were randomly allocated to receive either 80 mg tobramycin twice-daily continuous treatment or 300 mg tobramycin twice daily in cycles of 28 days on and 28 days off treatment. After three months, patients were switched to the alternative treatment regimen. A total of 32 patients with a mean (+/- SD) age of 18.5+/-8.6 years were included in the study. Compared with the treatment period using colistin, forced expiratory volume in 1 s decreased by -2.1+/-13.8% in the 80 mg tobramycin group and increased by +2.3+/-13.0% in the 300 mg group. Similar changes were observed in forced vital capacity (-2.5+/-12.9% in the 80 mg tobramycin group versus +2.5+/-9.6% in the 300 mg tobramycin group). Variability in responses was large but the differences were not statistically significant. Personal preference indicated that th...Continue Reading

Citations

Mar 18, 2011·The Cochrane Database of Systematic Reviews·Gerard RyanKerry Dwan
Mar 3, 2011·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Allan L CoatesMartin Charron
Dec 11, 2013·Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine·John LamMichael D Parkins
Aug 1, 2015·The Cochrane Database of Systematic Reviews·Matthew N HurleyPatrick Flume
Oct 31, 2018·The Cochrane Database of Systematic Reviews·Sherie SmithEdward Charbek
Jul 13, 2012·The Cochrane Database of Systematic Reviews·Lil Breen, Nivedita Aswani
Apr 3, 2018·The Cochrane Database of Systematic Reviews·Sherie SmithKate H Regan
Dec 14, 2012·The Cochrane Database of Systematic Reviews·Gerard RyanTracey Remmington

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Sanja StanojevicFelix Ratjen
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Warren LenneyJohn M Kovarik
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Stefanie HennigClaire E Wainwright
© 2022 Meta ULC. All rights reserved